FDA Approved: NULIBRY — Original Application (Sentynl Therapeutics, Inc.)

View source ↗

Summary

FDA approved NULIBRY (fosdenopterin hydrobromide) under an original application from Sentynl Therapeutics for the treatment of molybdenum cofactor deficiency ty…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Molybdenum Cofactor Deficiency Type

Drugs mentioned

• Nulibry (fosdenopterin)

Snippet

ORIG AP for NULIBRY (FOSDENOPTERIN HYDROBROMIDE)